Please login to bookmarkClose

GlaxoSmithKline has defeated claims by the ACCC that revised packaging for its now-discontinued pain killer Osteo Gel misled consumers. The drug maker will face penalties for earlier violations it admitted to, but the court hinted the damages will be nowhere near the $6 million competitor Reckitt Benckiser faced in a similar case.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au